

SPECTREM: Guselkumab Efficacy and Patient-Reported Outcomes Across Multiple High-Impact Sites in Participants With Low BSA, Moderate Psoriasis

Stephen K. Tyring,¹ Angela Y. Moore,^{2,3} Harrison Nguyen,^{4,5} Nicole Seminara,⁶ Henry Yu,⁷ Theodore Alkousakis,⁸ Olivia Chio,⁸ Katelyn Rowland,⁸ Daphne Chan,⁸ Jenny Jeyarajah,⁸ Lorne Albrecht^{9,10}

¹Center for Clinical Studies, Webster, TX, USA; ²Baylor University Medical Center, Dallas, TX, USA; ³Arlington Research Center, Arlington, TX, USA; ⁴Harrison Dermatology and Research Group, Houston, TX, USA; ⁵University of Houston, College of Medicine, Houston, TX, USA; ⁶Piedmont Plastic Surgery and Dermatology, Denver, NC, USA; ⁷West Derm Center, Bronx, NY, USA; ⁸Johnson & Johnson, Horsham and Spring House, PA, USA; ⁹Enverus Medical Research, Surrey, BC, Canada; ¹⁰University of British Columbia, Vancouver, BC, Canada



Scan the QR code. The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.

Key Takeaways

- ✓ SPECTREM enrolled a population that is often undertreated (i.e., low BSA psoriasis with high-impact site involvement). At baseline, >80% of participants had psoriasis affecting ≥2 high-impact sites
- ✓ After just 3 doses of GUS, 60–85% of participants achieved clear/almost clear skin (IGA 0/1) regardless of the number of high-impact sites involved
- ✓ A majority of GUS-randomized participants achieved meaningful improvements in itch and patient-reported quality of life, regardless of the number of high-impact sites involved

Background

SPECTREM was a phase 3b, multicenter, randomized, double-blind, placebo (PBO)-controlled study evaluating the efficacy and safety of guselkumab (GUS) in participants with low body surface area (BSA), moderate plaque psoriasis (PsO) involving ≥1 high-impact sites

Patients with low BSA PsO who may be more effectively treated with systemic therapies are underrepresented in clinical studies

SPECTREM was intentionally designed to address the undertreatment of patients with low BSA PsO involving high-impact sites, and most SPECTREM participants had more than one high-impact site involved

Objectives

To evaluate efficacy of GUS vs PBO in participants with at least moderate high-impact site involvement (site-specific IGA/PGA ≥3 at baseline) at Week 16 via:

- High-impact site-specific Investigator's Global Assessment (IGA)
 - Scalp-specific IGA (ss-IGA)
 - Facial IGA (f-IGA)
 - Intertriginous IGA (i-IGA)
 - Static Physician's Global Assessment of Genitalia (sPGA-G)
- Psoriasis Symptoms and Signs Diary (PSSD)
- Dermatology Life Quality Index (DLQI)
- Psoriasis Area and Severity Index (PASI)

Methods

Key inclusion criteria:


- IGA=3
- BSA=2–15% with ≥1 plaque outside of high-impact sites
- ≥1 high-impact sites with at least moderate severity (scalp, face, intertriginous, genital)

A total of 338 participants were randomized to receive GUS (N=225) or PBO (N=113)

Endpoints presented at Week 16 include:

- Primary endpoint: proportion of participants achieving IGA 0/1
- Proportions of participants achieving overall IGA 0/1 and PASI 90 by number of high-impact sites (one, two, three, or four sites*) at baseline

*Participants grouped into one, two, three, and four high-impact sites are mutually exclusive.



Results

Baseline demographics and disease characteristics were generally comparable between the PBO and GUS groups


	PBO (N=113)	GUS (N=225)	Total (N=338)
Demographics			
Age, yrs	44.5 (14.9)	47.0 (14.7)	46.2 (14.8)
Male	57 (50.4%)	116 (51.6%)	173 (51.2%)
White	83 (73.5%)	166 (73.8%)	249 (73.7%)
BMI, kg/m ²	31.0 (7.5)	30.9 (7.5)	30.9 (7.5)
Disease Characteristics			
PsO disease duration, yrs	14.0 (11.9)	18.4 (14.9)	16.9 (14.1)
IGA, moderate (3)	113 (100%)	224 (99.6%)*	337 (99.7%)
BSA, %	7.5 (3.7)	7.6 (3.7)	7.6 (3.7)
PASI (0–72)	9.0 (3.9)	9.1 (3.8)	9.0 (3.8)
Participants with any severity of PsO at high-impact sites (site-specific IGA/PGA ≥1)			
One site	18 (15.9%)	43 (19.1%)	61 (18.0%)
Two sites	43 (38.1%)	73 (32.4%)	116 (34.3%)
Three sites	29 (25.7%)	69 (30.7%)	98 (29.0%)
Four sites	23 (20.4%)	40 (17.8%)	63 (18.6%)
Participants with moderate-to-severe PsO at high-impact sites (site-specific IGA/PGA ≥3)			
One site	41 (36.3%)	81 (36.0%)	122 (36.1%)
Two sites	53 (46.9%)	91 (40.4%)	144 (42.6%)
Three sites	13 (11.5%)	40 (17.8%)	53 (15.7%)
Four sites	6 (5.3%)	13 (5.8%)	19 (5.6%)
Previous Medication Use			
Topical Agents* (N=338)	100%		
Phototherapy [†] (N=336)	18.5%		
Systemics* (N=336)	13.7%		
Advanced Orals [‡] (N=336)	4.5%		

Data shown are mean (SD), unless otherwise indicated. *One GUS-randomized participant deviated from the inclusion criteria with a baseline IGA score of 4. [†]Topical, anthralin, keratolytics, and tar; [‡]PVUVA and UVB; [§]PVUVA, methotrexate, cyclosporine, and acitretin; [¶]Apremilast and delamanid; ^{||}BSA=body surface area; ^{|||}BMI=body mass index; ^{||||}GUS=guselkumab; ^{|||||}IGA=Investigator's Global Assessment; ^{||||||}PASI=Psoriasis Area and Severity Index; ^{|||||||}PBO=placebo; ^{||||||||}PGA=Physician's Global Assessment; ^{|||||||||}PsO=psoriasis; ^{||||||||||}PVUVA=psoralen plus ultraviolet A; ^{|||||||||||}SD=standard deviation; ^{|||||||||||}UVB=ultraviolet B.

- No notable differences in baseline high-impact site involvement were observed between treatment groups
- At baseline, a majority of participants had PsO affecting two or more high-impact sites (any severity, site-specific IGA/PGA >0)
- Most participants assessed in this analysis had moderate-to-severe PsO (site-specific IGA/PGA ≥3) at one or two high-impact sites


Greater proportions of GUS-randomized participants had no effect of PsO on their quality of life compared to PBO-randomized participants at Week 16

- >44% of GUS-randomized participants achieved a DLQI score of 0/1 (no effect on quality of life) at Week 16, regardless of number of sites involved at baseline




*nominal p<0.05 GUS vs PBO; p-value is based on the chi-squared test, not adjusted for baseline stratification factor. NRI was used; participants who discontinued study agent due to lack of efficacy, worsening of PsO, or use of a prohibited PsO treatment prior to designated visit were considered nonresponders from that point forward. Participants with missing data were considered nonresponders. *Among participants with a baseline high-impact site assessment (ss-IGA, f-IGA, i-IGA, and/or sPGA-G) score ≥3 and a baseline DLQI score ≥3, GUS=guselkumab, f-IGA=facial IGA, i-IGA=intertriginous IGA, PBO=placebo, PsO=psoriasis, ss-IGA=Scalp-specific IGA, sPGA-G=Static Physicians Global Assessment of Genitalia.

GUS-randomized participant who achieved ss-IGA 0 at Week 16




GUS=guselkumab, ss-IGA=Scalp-specific IGA.

GUS-randomized participant who achieved f-IGA 0 at Week 16



GUS=guselkumab, f-IGA=facial IGA.


GUS-randomized participant who achieved i-IGA 0 at Week 16



Participant also had f-IGA=1 and ss-IGA=3 at Week 0 and achieved f-IGA=0 and ss-IGA=0 at Week 48. GUS=guselkumab, i-IGA=intertriginous IGA, ss-IGA=Scalp-specific IGA, f-IGA=facial IGA.

Proportions of participants achieving at least one high-impact site assessment score (ss-IGA, f-IGA, i-IGA, and/or sPGA-G) of 0/1 at Week 16


- In GUS-randomized participants with more than 1 high-impact site involved at baseline, more than 2/3 of participants achieved skin clearance (site-specific IGA/PGA 0/1) in all involved sites



Groups are mutually exclusive and include participants with baseline high-impact site scores ≥3 who achieved respective site scores of 0/1 at Week 16. Data are shown for groups with ≥10 participants. NRI was used; participants who discontinued study agent due to lack of efficacy, worsening of PsO, or use of a prohibited PsO treatment prior to designated visit were considered nonresponders from that point forward. Participants with missing data were considered nonresponders. *Among participants with a baseline high-impact site assessment (ss-IGA, f-IGA, i-IGA, and/or sPGA-G) score ≥3 and a baseline PASI total symptoms score ≥4, GUS=guselkumab, f-IGA=facial IGA, i-IGA=intertriginous IGA, PBO=placebo, PsO=psoriasis, PASI=Psoriasis Area and Severity Index, PSSD=Psoriasis Symptoms and Signs Diary, sPGA-G=Static Physicians Global Assessment of Genitalia, ss-IGA=Scalp-specific IGA.

Greater proportions of GUS-randomized participants achieved the primary endpoint (IGA 0/1) compared to PBO-randomized participants at Week 16


- ≥60% of GUS-randomized participants achieved IGA 0/1 across the number of high-impact sites involved at baseline



*nominal p<0.05 GUS vs PBO; p-value is based on the chi-squared test, not adjusted for baseline stratification factor. NRI was used; participants who discontinued study agent due to lack of efficacy, worsening of PsO, or use of a prohibited PsO treatment prior to designated visit were considered nonresponders from that point forward. Participants with missing data were considered nonresponders. *Among participants with a baseline high-impact site assessment (ss-IGA, f-IGA, i-IGA, and/or sPGA-G) score ≥3, f-IGA=facial IGA, GUS=guselkumab, i-IGA=intertriginous IGA, PBO=placebo, ss-IGA=Scalp-specific IGA, sPGA-G=Static Physicians Global Assessment of Genitalia.


The GUS groups achieved generally comparable mean changes from baseline in PSSD total symptoms scores at Week 16, regardless of number of high-impact sites involved at baseline

- Mean changes from baseline in PSSD total symptoms scores were >35 for the GUS groups across the number of sites involved at baseline



*nominal p<0.05 GUS vs PBO; p-value is based on the MMRM with explanatory variables of treatment group, visit, baseline score, an interaction term of visit with treatment group, and an interaction term of visit with baseline score. *Among participants with a baseline high-impact site assessment (ss-IGA, f-IGA, i-IGA, and/or sPGA-G) score ≥3, threshold for clinically meaningful improvement in PSSD symptoms score is ≥40 points. When participants discontinued study agent due to lack of efficacy, worsening of psoriasis, or use of a prohibited PsO treatment, zero change was assigned from that point onward. Missing data were handled by MMRM under missing at random assumption. GUS=guselkumab, f-IGA=facial IGA, i-IGA=intertriginous IGA, PBO=placebo, PSSD=Psoriasis Symptoms and Signs Diary, sPGA-G=Static Physicians Global Assessment of Genitalia, ss-IGA=Scalp-specific IGA.

74% of GUS-randomized participants achieved the primary endpoint (IGA 0/1) at Week 16



*p<0.001 GUS vs PBO; p-value is based on the Cochran-Mantel-Haenszel (CMH) test stratified by high-impact site (scalp, face, intertriginous, genital). NRI was used; participants who discontinued study agent due to lack of efficacy, worsening of PsO, or use of a prohibited PsO treatment prior to designated visit were considered nonresponders from that point forward. Participants with missing data were considered nonresponders. GUS=guselkumab, IGA=Investigator's Global Assessment, PBO=placebo, PsO=psoriasis.